Table 2 Treatment and outcome of 482 patients with S. aureus osteomyelitis.
Variable | Total (N = 482) | Patients with MRSA (N = 82) | Patients with MSSA (N = 400) | P value |
|---|---|---|---|---|
MRSA group vs. MSSA group | ||||
Antibiotic treatments, days | ||||
Intravenous | 14 | 14 | 14 | – |
Oral | 28 | 28 | 28 | – |
Surgery | ||||
Debridement | 482 (100) | 82 (100) | 400 (100) | – |
Bone grafts | 279 (59.7) | 55 (67.1) | 224 (56.0) | 0.067 |
Bone transportation | 64 (13.3) | 10 (12.2) | 54 (13.3) | 0.859 |
Flap coverage | 79 (16.4) | 21 (25.6) | 58 (14.5) | 0.021 |
Internal fixation | 235 (48.8) | 50 (61.0) | 185 (46.3) | 0.016 |
Adverse infection control | ||||
Infection persistence (repeated debridement) | 66 (13.7) | 20 (24.4) | 46 (11.5) | 0.004a |
Recurrence | 41 (8.5) | 5 (6.1) | 36 (9.0) | 0.516 |
Total hospital stay, median days | 31 (14–112) | 37.5 (14–112) | 31 (14–82) | < 0.001 |
Complications | 17 (3.5) | 7 (8.5) | 10 (2.5) | 0.015b |
Pathologic fracture | 4 (0.8) | 2 (2.4) | 2 (0.5) | |
Nonunion | 5 (1.0) | 0 (0) | 5 (0.8) | |
Amputation | 8 (1.7) | 5 (6.1) | 3 (0.8) | |
